Close Menu
Fund Focus News
    Facebook X (Twitter) Instagram
    Trending
    • What happens if your mutual fund or bank nominee passes away before you? Here’s what you should do next
    • Wall Street Money is Flowing into Ethereum ETFs and Out of Hyperliquid
    • UK savings deals: the heat is on as banks offer up to 8% | Savings
    • Metal ETFs shine in uncertain market: Should you invest now?
    • How a lumpsum calculator supports mutual fund investment decisions
    • Mutual fund companies earned more in Q1 as markets rose—but investors should look deeper
    • The AI Boom Is Expanding Beyond Chips. These 3 ETFs Could Be the Next Winners
    • Manulife Investments Announces July 2026 Cash Distributions for Manulife Exchange Traded Funds and ETF Series of Manulife Funds
    Facebook X (Twitter) Instagram
    Fund Focus News
    • Home
    • Bonds
    • ETFs
    • Funds
    • Investments
    • Mutual Funds
    • Property Investments
    • SIP
    Fund Focus News
    Home»Funds»COSCIENS Biopharma – Conclusion d’un accord de résolution avec Goodwood, Goodwood Fund et Puccetti Funds Management
    Funds

    COSCIENS Biopharma – Conclusion d’un accord de résolution avec Goodwood, Goodwood Fund et Puccetti Funds Management

    May 30, 2025


    Logo COSCIENS Biopharma Inc.

    COSCIENS Biopharma Inc, anciennement Aeterna Zentaris Inc, est une société biopharmaceutique spécialisée dans le développement et la commercialisation d’un portefeuille diversifié de produits pharmaceutiques et diagnostiques, y compris ceux qui sont axés sur des domaines où les besoins médicaux ne sont pas satisfaits. Son produit principal, la macimoréline (Macrilen ; Ghryvelin), est un test oral indiqué pour le diagnostic de la déficience en hormone de croissance chez l’adulte (DHCA). La société est également engagée dans le développement d’actifs thérapeutiques et d’une technologie d’extraction propriétaire, qui est appliquée à la production d’ingrédients actifs à partir de ressources végétales renouvelables utilisées dans les produits cosméceutiques (c’est-à-dire le bêta-glucane d’avoine et les avenanthramides, que l’on trouve dans des marques de produits de soins de la peau comme Aveeno et Burt’s Bees) et qui sont en cours de développement en tant que nutraceutiques et/ou produits pharmaceutiques potentiels.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email

    Related Posts

    Active funds vs passive: Is active management still relevant?

    July 24, 2026

    The Best Large-Growth Funds and ETFs to Buy

    July 24, 2026

    SBI Funds Management vs HDFC AMC: Which AMC Stock is Better – Stock Insights News

    July 24, 2026
    Leave A Reply Cancel Reply

    Top Posts

    What happens if your mutual fund or bank nominee passes away before you? Here’s what you should do next

    July 25, 2026

    The Shifting Landscape of Art Investment and the Rise of Accessibility: The London Art Exchange

    September 11, 2023

    Charlie Cobham: The Art Broker Extraordinaire Maximizing Returns for High Net Worth Clients

    February 12, 2024

    The Unyielding Resilience of the Art Market: A Historical and Contemporary Perspective

    November 19, 2023
    Don't Miss
    Mutual Funds

    What happens if your mutual fund or bank nominee passes away before you? Here’s what you should do next

    July 25, 2026

    When you invest in a mutual fund, buy insurance, or open a bank account, picking…

    Wall Street Money is Flowing into Ethereum ETFs and Out of Hyperliquid

    July 25, 2026

    UK savings deals: the heat is on as banks offer up to 8% | Savings

    July 24, 2026

    Metal ETFs shine in uncertain market: Should you invest now?

    July 24, 2026
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    EDITOR'S PICK

    Specialised investment funds for all market cycles – Market News

    October 31, 2025

    Spot bitcoin ETFs log highest net inflows since July after Fed’s Powell nods to rate cuts

    August 26, 2024

    The 10 best- and worst-performing passive ETFs of the past 3 years

    March 17, 2025
    Our Picks

    What happens if your mutual fund or bank nominee passes away before you? Here’s what you should do next

    July 25, 2026

    Wall Street Money is Flowing into Ethereum ETFs and Out of Hyperliquid

    July 25, 2026

    UK savings deals: the heat is on as banks offer up to 8% | Savings

    July 24, 2026
    Most Popular

    🔥Juve target Chukwuemeka, Inter raise funds, Elmas bid in play 🤑

    August 20, 2025

    💵 Libra responds after Flamengo takes legal action and ‘freezes’ funds

    September 26, 2025

    ₹9000 monthly SIP can help you retire at 45 with ₹2 lakh monthly pension

    May 5, 2026
    © 2026 Fund Focus News
    • Get In Touch
    • Privacy Policy
    • Terms and Conditions

    Type above and press Enter to search. Press Esc to cancel.